Amgen’s AMG-133 Phase 1 bone data ‘seems non-issue,’ says Jefferies
Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which ...
Business Insider1mon
Buy Rating Affirmed: Amgen’s Strategic Advancements in Obesity Drug Pipeline
Amgen has initiated a new Phase I trial for AMG-513, an innovative drug candidate with potential indications for obesity, which is a significant move consistent with the company’s broader ...
Nasdaq1mon
Bernstein Initiates Coverage of Amgen (XTRA:AMG) with Outperform Recommendation
There are 4,096 funds or institutions reporting positions in Amgen. This is an increase of 50 owner(s) or 1.24% in the last quarter. Average portfolio weight of all funds dedicated to AMG is 0.55% ...